Transfer of modified fecal viromes improve blood glucose regulation and alleviates symptoms of metabolic dysfunction-associated fatty liver disease in an obesity male mouse model

Xiaotian Mao,Sabina Birgitte Larsen,Line Sidsel Fisker Zachariassen,Anders Brunse,Signe Adamberg,Josue Leonardo Castro Mejia,Frej Larsen,Kaarel Adamberg,Dennis Sandris Nielsen,Axel Kornerup Hansen,Camilla Hartmann Friis Hansen,Torben Sølbeck Rasmussen

DOI: https://doi.org/10.1101/2023.03.20.532903

2024-04-12

Abstract:Metabolic syndrome encompasses amongst other conditions like obesity, type-2 diabetes, and metabolic dysfunction associated fatty liver disease (MAFLD), which are all associated with gut microbiome (GM) dysbiosis. Fecal microbiota transplantation (FMT) has been explored to treat metabolic syndrome by restoring the GM. FMT is generally safe, but motivated by case reports, accidental transfer of pathogenic bacteria remains a concern. As a safer alternative, fecal virome transplantation (FVT, sterile-filtrated feces) has the advantage over FMT in that mainly bacteriophages are transferred and FVT from lean male donors has shown promise in alleviating the metabolic effects of a high-fat diet in a preclinical mouse study. However, FVT still carries the risk of eukaryotic viral infections. To address this, we here apply recently developed modification methodologies to inactivate or remove the eukaryotic viral component of FVT while maintaining an active enteric bacteriophage community. Modified FVTs were compared with unmodified FVT and saline in an animal model of diet-induced obesity using male C57BL/6N mice. In contrast to the obese control group, mice administered a modified FVT, nearly depleted from eukaryotic viruses (0.1%), exhibited enhanced blood glucose clearance, although without a concurrent reduction in weight gain. The unmodified FVT improved liver pathology and reduced the proportions of immune cells in the adipose tissue with a non-uniform response. GM analysis suggested that bacteriophage-mediated GM modulation had influenced these outcomes. When optimized, this may pave the way for developing safe bacteriophage-based therapies targeting metabolic syndrome through GM restoration.

Microbiology

What problem does this paper attempt to address?

The paper aims to address issues related to metabolic syndrome, particularly obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD). Specifically, the researchers attempt to improve these symptoms through a modified fecal virome transplantation (FVT) method. Compared to traditional fecal microbiota transplantation (FMT), FVT has advantages in terms of safety because it primarily transfers bacteriophages rather than bacteria. However, unmodified FVT still carries the risk of eukaryotic virus infections. Therefore, the researchers developed new methods to inactivate or remove eukaryotic viral components in FVT while maintaining the activity of the gut bacteriophage population. By comparing the effects of differently treated FVT with untreated FVT and saline control groups, the researchers hope to find a safer and more reproducible alternative to alleviate the symptoms of metabolic syndrome and achieve this goal through phage-mediated restoration of the gut microbiota. Specifically, the study used male mouse models to evaluate the safety and efficacy of these modified FVTs.